Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication
- PMID: 40664215
- PMCID: PMC12276844
- DOI: 10.1016/j.cmet.2025.06.009
Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication
Abstract
Pancreatic alpha cells modulate beta cell function in a paracrine manner through the release of glucagon. However, the detailed molecular architecture underlying alpha-to-beta cell regulation remains poorly characterized. Here, we show that the glucagon-like peptide-1 receptor (GLP1R) is enriched as nanodomains on beta cell membranes that contact alpha cells, in keeping with increased single-molecule transcript expression. At low glucose, beta cells next to alpha cells directly sense micromolar glucagon release by pre-internalizing GLP1R. Pre-internalized GLP1R is associated with earlier beta cell Ca2+ responses to high glucose, which are then propagated across the islet. Beta cells adjacent to alpha cells are more secretory than beta cells next to other beta cells. Localized GLP1R signaling occurs in vitro and in vivo, is operative in the post-prandial state, and GLP1R contacts decrease between beta cells and alpha cells during metabolic stress. Thus, we detail a regulated pathway through which glucagon modulates insulin release.
Keywords: Ca(2+); GLP1R; alpha cell; beta cell; diabetes; glucagon; insulin; islet; pancreas; signaling.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.C., A.E., and C.Ä. are employees of Novo Nordisk A/S. J.E.C. has received funding for research from Eli Lilly, Novo Nordisk, Merck, Structure Therapeutics, Fractyl Therapeutics, Alticore, and Prostasis. J.E.C. has served as a consultant/advisory in the past 12 months with Arrowhead Therapeutics, Boehringer Ingelheim, Neurocrine Biosciences, Protagonist Therapeutics, Prostasis, and Structure Therapeutics. A. Kleinridders has received speaker’s fees from Novo Nordisk A/S and Daiichi Sankyo. D.J.H. and J.B. have filed a patent on GLP1R and GIPR chemical probes. D.J.H. and J.B. receive licensing revenue from Celtarys Research for provision of GLP1R/GIPR chemical probes. D.J.H., A.H.S. and K.V. have filed patents related to type 2 diabetes therapy and GLP1R agonism.
References
-
- Sasson A, Rachi E, Sakhneny L, Baer D, Lisnyansky M, Epshtein A, and Landsman L (2016). Islet Pericytes Are Required for β-Cell Maturity. Diabetes 65, 3008–3014. - PubMed
-
- Gan WJ, Do OH, Cottle L, Ma W, Kosobrodova E, Cooper-White J, Bilek M, and Thorn P (2018). Local Integrin Activation in Pancreatic β Cells Targets Insulin Secretion to the Vasculature. Cell Rep. 24, 2819–2826.e2813. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
